DNA
Ginkgo Bioworks HoldingsKey Statistics
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings (DNA) is a frontrunner in the synthetic biology industry, leveraging cutting-edge genetic engineering techniques to develop tailored bioengineered organisms for diverse applications in pharmaceuticals, agriculture, and industrial biotechnology. The company’s innovative platform enhances cellular design for manufacturing, optimizing product development and streamlining production processes. With a strong focus on solving critical global challenges, including climate change and food security, Ginkgo is well-positioned to influence multiple sectors while fostering sustainable advancements in biotechnology. As the industry evolves, Ginkgo's commitment to bio-based solutions positions it for significant growth and impact.
Fundamentals
| Revenue (TTM) | $170.16M |
| Gross Profit (TTM) | $123.18M |
| EBITDA | $-267.82M |
| Operating Margin | -209.70% |
| Return on Equity | -51.10% |
| Return on Assets | -15.40% |
| Revenue/Share (TTM) | $3.07 |
| Book Value | $8.74 |
| Price-to-Book | 0.95 |
| Price-to-Sales (TTM) | 2.89 |
| EV/Revenue | 2.937 |
| EV/EBITDA | -1.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -23.80% |
| Shares Outstanding | $49.94M |
| Float | $41.62M |
| % Insiders | 4.06% |
| % Institutions | 72.99% |
Historical Volatility
Volatility is currently contracting